Kuen-Feng Chen

List of Publications by Year
in descending order

89	4,849	76196	98622
papers	citations	40 h-index	67 g-index

96	96	96	6830
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 155-161.	1.3	270
2	Treatment of Liver Cancer. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a021535.	2.9	241
3	3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells. Cancer Research, 2004, 64, 1444-1451.	0.4	225
4	Thiazolidenediones Mediate Apoptosis in Prostate Cancer Cells in Part through Inhibition of Bcl-xL/Bcl-2 Functions Independently of PPARÎ³. Cancer Research, 2005, 65, 1561-1569.	0.4	206
5	Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death and Disease, 2013, 4, e485-e485.	2.7	175
6	Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3. Clinical Cancer Research, 2010, 16, 5189-5199.	3.2	155
7	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. Journal of Hepatology, 2011, 55, 1041-1048.	1.8	149
8	CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene, 2010, 29, 6257-6266.	2.6	147
9	OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Speciesâ€“Related Autophagy in Hepatocellular Carcinoma. Cancer Research, 2008, 68, 9348-9357.	0.4	131
10	Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1â€“Mediated Inhibition of STAT3. Molecular Cancer Therapeutics, 2012, 11, 452-463.	1.9	119
11	Peroxisome Proliferator-Activated Receptor Î³-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells. Molecular Pharmacology, 2005, 67, 1342-1348.	1.0	113
12	Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2008, 68, 6698-6707.	0.4	109
13	CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Research, 2012, 14, R68.	2.2	105
14	Nilotinib Induces Autophagy in Hepatocellular Carcinoma through AMPK Activation. Journal of Biological Chemistry, 2013, 288, 18249-18259.	1.6	82
15	Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2Aâ€“dependent phospho-Akt inactivation in estrogen receptorâ€“negative human breast cancer cells. Breast Cancer Research, 2014, 16, 431.	2.2	80
16	Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway. Journal of Biological Chemistry, 2009, 284, 11121-11133.	1.6	79
17	STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 5768-5776.	3.2	78
18	Induction of DNA Damage-Inducible Gene GADD45Î² Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2010, 70, 9309-9318.	0.4	76

#	Article	IF	Citations
19	Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. European Journal of Medicinal Chemistry, 2012, 55, 220-227.	2.6	75
20	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7243-7248.	3.3	65
21	Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood, 2005, 105, 4021-4027.	0.6	64
22	Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. Journal of Hepatology, 2010, 52, 88-95.	1.8	64
23	Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Research, 2013, 15, R63.	2.2	63
24	Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology, 2014, 59, 190-201.	3.6	63
25	Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients. PLoS ONE, 2014, 9, e89389.	1.1	57
26	CIP2A Is a Predictor of Poor Prognosis in Colon Cancer. Journal of Gastrointestinal Surgery, 2012, 16, 1037-1047.	0.9	56
27	Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced Î²-catenin activation. Cell Death and Disease, 2019, 10, 420.	2.7	55
28	Functional Characterization of Glycine N-Methyltransferase and Its Interactive Protein DEPDC6/DEPTOR in Hepatocellular Carcinoma. Molecular Medicine, 2012, 18, 286-296.	1.9	54
29	CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncology, 2012, 48, 585-593.	0.8	54
30	Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasiaâ€“mutated kinaseâ€“mediated DNA damage response. European Journal of Cancer, 2018, 102, 10-22.	1.3	54
31	Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochemical Pharmacology, 2012, 84, 268-277.	2.0	52
32	Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death and Disease, 2014, 5, e1359-e1359.	2.7	52
33	Palbociclib induces activation of <scp>AMPK</scp> and inhibits hepatocellular carcinoma in a <scp>CDK</scp>4/6â€independent manner. Molecular Oncology, 2017, 11, 1035-1049.	2.1	52
34	SHP-1 is a target of regorafenib in colorectal cancer. Oncotarget, 2014, 5, 6243-6251.	0.8	50
35	A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Cancer Letters, 2012, 321, 27-35.	3.2	48
36	Sorafenib Enhances Radiation-Induced Apoptosis in Hepatocellular Carcinoma by Inhibiting STAT3. International Journal of Radiation Oncology Biology Physics, 2013, 86, 456-462.	0.4	47

#	Article	IF	Citations
37	Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Oncotarget, 2016, 7, 64136-64147.	0.8	46
38	Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochemical Pharmacology, 2013, 85, 356-366.	2.0	43
39	Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget, 2015, 6, 2164-2179.	0.8	43
40	Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget, 2016, 7, 9135-9149.	0.8	43
41	SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma. Neoplasia, 2014, 16, 595-605.	2.3	42
42	Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy. International Journal of Molecular Sciences, 2017, 18, 1234.	1.8	41
43	Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica, 2013, 98, 729-738.	1.7	40
44	Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochemical Pharmacology, 2012, 83, 769-777.	2.0	39
45	Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A. Molecular Cancer Therapeutics, 2011, 10, 892-901.	1.9	37
46	Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. Scientific Reports, 2016, 6, 28888.	1.6	37
47	Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome. PLoS ONE, 2013, 8, e55705.	1.1	37
48	Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells. Neoplasia, 2012, 14, 463-IN3.	2.3	36
49	EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. European Journal of Cancer, 2017, 72, 112-123.	1.3	35
50	Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorganic and Medicinal Chemistry, 2012, 20, 6144-6153.	1.4	34
51	Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma. Hepatology, 2016, 63, 1528-1543.	3.6	34
52	Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity. Journal of Hepatology, 2014, 61, 89-97.	1.8	33
53	A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Cancer Letters, 2016, 371, 205-213.	3.2	31
54	Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. European Journal of Medicinal Chemistry, 2011, 46, 2845-2851.	2.6	29

#	Article	IF	Citations
55	Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Letters, 2012, 317, 9-15.	3.2	29
56	CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. Lung Cancer, 2014, 85, 152-160.	0.9	29
57	Sorafenib analogue <scp>SC</scp>â€60 induces apoptosis through the <scp>SHP</scp>â€1/<scp>STAT</scp>3 pathway and enhances docetaxel cytotoxicity in tripleâ€negative breast cancer cells. Molecular Oncology, 2017, 11, 266-279.	2.1	29
58	The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells. Experimental and Molecular Medicine, 2017, 49, e366-e366.	3.2	29
59	RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget, 2014, 5, 4909-4919.	0.8	28
60	SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A. Oncotarget, 2016, 7, 638-655.	0.8	28
61	TD-19, an Erlotinib Derivative, Induces Epidermal Growth Factor Receptor Wild-Type Nonsmall-Cell Lung Cancer Apoptosis through CIP2A-Mediated Pathway. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 352-358.	1.3	27
62	Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy. World Journal of Gastroenterology, 2014, 20, 15269.	1.4	27
63	Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer. Neoplasia, 2015, 17, 687-696.	2.3	25
64	Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 685-694.	1.5	22
65	Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists. European Journal of Medicinal Chemistry, 2012, 56, 127-133.	2.6	21
66	RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Carcinogenesis, 2014, 35, 2807-2814.	1.3	20
67	A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3. Cancer Letters, 2014, 349, 136-143.	3.2	20
68	Protein phosphatase 5 promotes hepatocarcinogenesis through interaction with AMP-activated protein kinase. Biochemical Pharmacology, 2017, 138, 49-60.	2.0	20
69	Sorafenib and its derivative <scp>SC</scp>â€49 sensitize hepatocellular carcinoma cells to <scp>CS</scp>â€1008, a humanized antiâ€TNFRSF10B<scp> (DR</scp>5) antibody. British Journal of Pharmacology, 2013, 168, 658-672.	2.7	19
70	Sorafenib Action in Hepatitis B Virus Xâ€“Activated Oncogenic Androgen Pathway in Liver through SHP-1. Journal of the National Cancer Institute, 2015, 107, djv190.	3.0	19
71	Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation. Lung Cancer, 2017, 112, 81-89.	0.9	18
72	Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget, 2017, 8, 65077-65089.	0.8	18

#	Article	IF	Citations
73	Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. BMC Cancer, 2015, 15, 301.	1.1	17
74	Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. Breast Cancer Research and Treatment, 2014, 146, 71-84.	1.1	16
75	Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. Journal of Molecular Medicine, 2017, 95, 965-975.	1.7	16
76	Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling. International Journal of Radiation Oncology Biology Physics, 2016, 95, 761-771.	0.4	14
77	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Scientific Reports, 2017, 7, 1728.	1.6	13
78	TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1. Cancer Letters, 2021, 498, 142-151.	3.2	13
79	Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 488-496.	0.5	11
80	SCâ€1, a sorafenib derivative, shows antiâ€tumor effects in osteogenic sarcoma cells. Journal of Orthopaedic Research, 2013, 31, 335-342.	1.2	9
81	Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition. Molecules, 2013, 18, 15398-15411.	1.7	9
82	Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma. Scientific Reports, 2016, 6, 35308.	1.6	9
83	Carfilzomib induces leukaemia cell apoptosis via inhibiting <scp>ELK</scp>1/<scp>KIAA</scp>1524 (Elkâ€1/<scp>CIP</scp>2A) and activating <scp>PP</scp>2A not related to proteasome inhibition. British Journal of Haematology, 2017, 177, 726-740.	1.2	9
84	Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 410-421.	1.3	9
85	SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Antiâ€“Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model. Molecular Cancer Therapeutics, 2014, 13, 27-36.	1.9	7
86	Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma. Liver International, 2018, 38, 2248-2259.	1.9	7
87	SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma. Oncotarget, 2016, 7, 22193-22205.	0.8	6
88	Copperâ€“obatoclax derivative complexes mediate DNA cleavage and exhibit anti-cancer effects in hepatocellular carcinoma. Chemico-Biological Interactions, 2015, 228, 108-113.	1.7	4
89	Sensitization of hepatocellular carcinoma (HCC) to tigatuzumab (CS-1008), a humanized anti-DR5 antibody, by sorafenib and its derivative SC-49.. Journal of Clinical Oncology, 2012, 30, e14516-e14516.	0.8	0